Cowden Syndrome

What is it?

Cowden syndrome (CS) is a rare inherited condition caused by a mutation in the PTEN gene, which normally helps control cell growth. The hallmark of the disease is the development of multiple benign (non-cancerous) growths — called hamartomas — on the skin, mucous membranes, and internal organs. More importantly, Cowden syndrome significantly increases the lifetime risk of developing certain cancers, particularly of the breast, thyroid, and uterus. Cowden syndrome belongs to a group of conditions collectively known as PTEN hamartoma tumor syndrome (PHTS).

Who is affected?

Cowden syndrome is rare, but likely underdiagnosed because its signs can be subtle and develop gradually.

• Prevalence: Approximately 1 in 200,000 people
• Inheritance: Autosomal dominant — a single copy of the altered gene inherited from one parent is sufficient to cause the condition; each child of an affected parent has a 50% chance of inheriting it
• Age of onset: Mucocutaneous (skin and mucous membrane) lesions typically appear in the late teens to twenties; cancer risks increase from the thirties onward
• Sex: Affects both sexes equally, though cancer types differ — breast and endometrial cancer primarily affect women

What causes it?

Cowden syndrome is caused by mutations in the PTEN gene, located on chromosome 10.

• PTEN function: PTEN is a tumour suppressor gene — it produces a protein that regulates cell growth and division. When PTEN is mutated, cells can grow and divide in an uncontrolled manner
• Inheritance pattern: Autosomal dominant with variable expressivity — family members carrying the same mutation may develop very different manifestations
• Penetrance: Nearly complete for mucocutaneous features (>99% by age 30), but variable for cancer
• PTEN-negative cases: Approximately 25–35% of patients who meet clinical diagnostic criteria do not have a detectable PTEN mutation; other genes may be involved

What are the clinical features?

The skin is the most consistently affected organ, with over 99% of patients developing mucocutaneous lesions by their late twenties. These lesions are benign but serve as critical diagnostic clues.

• Trichilemmomas: Small (1–5 mm), skin-coloured or slightly yellowish papules on the face, especially around the nose, mouth, and ears — the most characteristic skin finding
• Oral papillomas: Small papules on the lips, gums, and inner cheeks that can merge into a cobblestone pattern; may also give the tongue a furrowed (scrotal) appearance
• Acral keratoses: Flat-topped, wart-like papules (1–4 mm) on the backs of the hands and feet
• Palmoplantar keratoses: Translucent, hard papules on the palms and soles, sometimes with a central pit
• Macrocephaly: An abnormally large head circumference, present in most patients (85–100% of children with PHTS)
• Lipomas: Benign fatty tumours under the skin; present in approximately 35–57% of patients

Other features may include penile freckling in males (19–54%), vascular malformations, and gastrointestinal polyps.

How is it diagnosed?

Diagnosis is based on clinical criteria combined with genetic testing.

• Clinical assessment: Recognition of multiple mucocutaneous lesions (trichilemmomas, oral papillomas, acral keratoses) combined with macrocephaly and/or a personal or family history of characteristic cancers
• Revised diagnostic criteria (NCCN): Major criteria include breast cancer, thyroid carcinoma (especially follicular), endometrial cancer, macrocephaly, Lhermitte-Duclos disease (cerebellar hamartoma), and multiple mucocutaneous lesions. Minor criteria include colorectal cancer, renal cell carcinoma, lipomas (≥3), autism spectrum disorder, and vascular anomalies
• Genetic testing: PTEN gene sequencing confirms the diagnosis; recommended for all patients meeting clinical criteria and for at-risk family members
• Skin biopsy: Histopathology of trichilemmomas shows a characteristic lobular proliferation of clear cells with peripheral palisading on a thickened basement membrane
• Dermoscopy: Trichilemmomas show a radiated red iris-like structure

What treatment options are available?

There is no cure for Cowden syndrome. Management focuses on cancer surveillance and treatment of symptomatic lesions.

Cancer surveillance (lifelong):

• Breast: Annual breast MRI from age 25; mammography added from age 40. Discussion of risk-reducing mastectomy from age 25
• Thyroid: Baseline thyroid ultrasound from age 12; repeated every 3–5 years (or every 2–3 years if nodules are found)
• Colon: Baseline colonoscopy at age 35–40
• Endometrium: Education about abnormal bleeding from age 30–35
• Kidney: Consider renal ultrasound every 2 years from age 35–40

Skin lesion management:

• Trichilemmomas are benign and do not require treatment unless cosmetically bothersome — can be removed by excision, laser (CO₂), or electrosurgery
• Oral papillomas may be treated with topical retinoids, though they tend to recur after stopping treatment
• Acral and palmoplantar keratoses can be treated with topical keratolytics or cryotherapy

Emerging therapies:

• mTOR inhibitors (sirolimus) have shown improvement in mucocutaneous lesions in pilot studies

Key points for patients

• Cowden syndrome is a lifelong condition that requires ongoing cancer surveillance — early detection is the best protection
• The mucocutaneous lesions (skin growths, oral papules, hand keratoses) are benign and not dangerous in themselves, but they are important warning signs that should prompt genetic evaluation
• When to seek medical attention: A family history of multiple cancers (especially breast, thyroid, uterine) combined with skin papules or a large head circumference; any new lumps, unusual bleeding, or persistent symptoms
• Genetic counselling is recommended for all affected individuals and at-risk family members — each child of an affected parent has a 50% chance of inheriting the condition
• Cowden syndrome is likely underdiagnosed — if you recognise these features in yourself or a family member, consult a dermatologist or geneticist